

Final Report Date:	04-10-2023 10:01	Specimen Collected:	03-10-2023 10:00
Accession ID:	2304100001	Specimen Received:	03-10-2023 10:00

Fungal Antibodies Summary

Panel Name	Organism	Positive Serology		PCR
		IGG	IGM	
Candida	Candida	Candida albicans	Candida albicans	N/A
Saccharomyces	Saccharomyces			N/A
Cladosporium	Cladosporium			N/A
Trichosporon	Trichosporon			N/A



Final Report Date:	04-10-2023 10:01	Specimen Collected:	03-10-2023 10:00
Accession ID:	2304100001	Specimen Received:	03-10-2023 10:00

LAST NAME	FIRST NAME	GENDER	DATE OF BIRTH	ACCESSION ID	DATE OF SERVICE
PATIENT	TEST2	MALE	2000-10-27	2304100001	03-10-2023 10:00

PATIENT

Name: TEST2 PATIENT
Date of Birth: 2000-10-27
Gender: Male
Age: 22

City: SAN CARLOS
State: CA Zip #: 94070

Fasting: FASTING

PROVIDER

Practice Name: Vibrant IT4 Practice
Provider Name: Demo Client, DDD (999994)
Street Address: TEST STREET
City: TEST CITY
State: KY
Zip #: 42437
Telephone #:
Fax #: 000-000-0000

Vibrant Wellness is pleased to present to you, IBSSure, to help you make healthy lifestyle choices in consultation with your physicians and dietitians. It is intended to be used as a tool to encourage a general state of health and well-being.

Vibrant IBSSure is a tool to determine IgG antibodies to 2 antigens – Vinculin and Cytolethal Distending Toxin B (CdtB) tested using a chemiluminescent technology delivering high sensitivity and specificity of detection.

Interpretation of Report: The following terminologies are used consistently in the report and are explained below.


Interpretation of Report: The test results of IgG antibody levels to Vinculin and CdtB are calculated by comparing the average intensity of the respective antibody to that of a healthy reference population. Reference ranges have been established using a sample cohort comprising of 96 IBS-D, 96 IBD, 96 celiac and 192 healthy serum samples. The results are displayed in 3 columns surrounded by GREEN (In Control), YELLOW (Moderate) or RED (High Risk) box. Related information and comments will populate if you have a YELLOW or RED result for any of the tests.


The Vibrant Wellness platform provides tools for you to track and analyze your general wellness profile. Testing for IBSSure offered by Vibrant Wellness is performed by Vibrant America LLC, a CLIA certified lab CLIA#:05D2078809. Vibrant Wellness provides and makes available this report and any related services pursuant to the Terms of Use Agreement (the "Terms") on its website at www.vibrant-wellness.com. By accessing, browsing or otherwise using the report or website or any services, you acknowledge that you have read, understood, and agree to be bound by these terms. If you do not agree to accept these terms, you shall not access, browse or use the report or website. The statements in this report have not been evaluated by the Food and Drug Administration and are only meant to be lifestyle choices for potential risk mitigation. Please consult your Physician/Dietitian for medication, treatment or life style management. This product is not intended to diagnose, treat, or cure any disease.

Please Note - It is important that you discuss any modifications to your diet, exercise and nutritional supplementation with your physician before making any changes.

Final Report Date:	04-10-2023 10:01	Specimen Collected:	03-10-2023 10:00
Accession ID:	2304100001	Specimen Received:	03-10-2023 10:00

IBSSure							
Test name	In Control	Moderate	High Risk	In Control Range	Moderate Range	High Risk Range	Previous
Anti-Vinculin IgG			26.0	≤10.0	10.1~20.0	≥20.1	
Anti-Cytolethal Distending Toxin B IgG			>30.0	≤10.0	10.1~20.0	≥20.1	

 **Comments**
 Elevated antibodies to Vinculin suggest likely IBS-D or IBS-M. It can likely differentiate from IBD.;
 Elevated antibodies to Cytolethal Distending Toxin B suggest likely IBS-D or IBS-M.



Test Risk and Limitations

This test is not intended to be used as a diagnostic tool for SIBO rather as an inclusive tool to help tell whether your cramps, gassiness, bloating, and diarrhea are being caused by a type of irritable bowel syndrome (IBS).

IBSSure testing is performed at Vibrant America laboratory, and utilizes ISO-13485 developed technology. However, laboratory error can occur, which might lead to incorrect results. Some of them may include sample mislabeling or contamination, operational error or failure to obtain data for certain proteins. Vibrant's laboratory may need a second sample to complete the testing.

Vibrant America has effective procedures in place to protect against technical and operational problems. However, such problems may still occur. Examples include failure to obtain the result for a specific protein due to circumstances beyond Vibrant's control. Vibrant may re-test a sample in order to obtain these results but upon re-testing the results may still not be obtained. As with all medical laboratory testing, there is a small chance that the laboratory could report incorrect results. A tested individual may wish to pursue further testing to verify any results.

The general wellness test intended uses relate to sustaining or offering general improvement to functions associated with a general state of health while making reference to diseases or conditions. This test has been laboratory developed and its performance characteristics determined by Vibrant America LLC, a CLIA and CAP certified laboratory performing the test. The test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.

A limitation of this testing is that most scientific studies have been performed in Caucasian populations only. The interpretations and recommendations are done in the context of Caucasian studies, but the results may or may not be relevant to tested individuals of different or mixed ethnicities. Please note that pediatric ranges have not been established for these tests. Interference studies have not been established for individuals on immunosuppressive drugs.

Based on test results and other medical knowledge of the tested individual, health care providers might consider additional independent testing, or consult another health care provider or genetic counselor.

References

1. Lin, Henry C. "Small Intestinal Bacterial Overgrowth: A Framework for Understanding Irritable Bowel Syndrome." *Jama* 292.7 (2004): 852. Web.
2. Pimentel Mark, Walter Morales, Ali Rezaie, Emily Marsh, Anthony Lembo, James Mirocha, Daniel A. Leffler, Zachary Marsh, Stacy Weitsman, Kathleen S. Chua, Gillian M. Barlow, Enoch Bortey, William Forbes, Allen Yu, and Christopher Chang. "Development and Validation of a Biomarker for Diarrhea-Predominant Irritable Bowel Syndrome in Human Subjects." *PLOS ONE* 10.5 (2015): n. pag. Web.
3. Pimentel Mark, Walter Morales, Venkata Pokkunuri, Constantinos Brikos, Sun Moon Kim, Seong Eun Kim, Konstantinos Triantafyllou, Stacy Weitsman, Zachary Marsh, Emily Marsh, Kathleen S. Chua, Shanthi Srinivasan, Gillian M. Barlow, and Christopher Chang. "Autoimmunity Links Vinculin to the Pathophysiology of Chronic Functional Bowel Changes Following *Campylobacter* Jejuni Infection in a Rat Model." *Dig Dis Sci Digestive Diseases and Sciences* 60.5 (2014): 1195-205. Web.
4. Pimentel Mark, Walter Morales, Ali Rezaie, Emily Marsh, Anthony Lembo, Daniel A. Leffler, Stacy Weitsman, Kathleen S. Chua, Gillian M. Barlow, Enoch Bortey. "Assessment of Anti-vinculin and Anti-cytotolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome." *Dig Dis Sci: Digestive Disease and Science*. 62.6 (2017)

Final Report Date:	04-10-2023 10:01	Specimen Collected:	03-10-2023 10:00
Accession ID:	2304100001	Specimen Received:	03-10-2023 10:00

LAST NAME	FIRST NAME	GENDER	DATE OF BIRTH	ACCESSION ID	DATE OF SERVICE
PATIENT	TEST2	MALE	2000-10-27	2304100001	03-10-2023 10:00

PATIENT

Name: TEST2 PATIENT
 Date of Birth: 2000-10-27
 Gender: Male
 Age: 22

City: SAN CARLOS
 State: CA Zip #: 94070

Fasting: FASTING

PROVIDER

Practice Name: Vibrant IT4 Practice
Provider Name: Demo Client, DDD (999994)
 Street Address: TEST STREET
 City: TEST CITY
 State: KY
 Zip #: 42437
 Telephone #:
 Fax #: 000-000-0000

Vibrant Wellness is pleased to present to you, '**Fungal Antibodies**', to help you make healthy lifestyle, dietary and treatment choices in consultation with your healthcare provider. It is intended to be used as a tool to encourage a general state of health and well-being.

The Vibrant Fungal Antibodies is a test to measure antibody levels to fungal microorganisms in one's blood. The panel is designed to give a complete picture of an individual's levels of antibodies to these antigens in serum.

Interpretation of Report: The report begins with the Fungal Antibodies summary page which lists only the microorganisms against which the antibody levels are high or moderate in the reference range. Following the summary section is the complete list of the fungal antibodies along with the levels of antibodies to them in a tabular form to enable a full overview along with the corresponding reference ranges. The level of the antibody has a green, yellow or red highlight around the cell indicating –Mild, Moderate or High levels in comparison to our reference population. Additionally, the previous value is also indicated to help check for improvements every time the test is ordered. All contents provided are purely for informational purposes only and should not be considered medical advice. Any changes based on these choices are to be made in consultation with the clinical provider.

The Vibrant Wellness platform provides tools for you to track and analyze your general wellness profile. Testing for the fungal antibodies panel is performed by Vibrant America, a CLIA certified lab CLIA#:05D2078809. Vibrant Wellness provides and makes available this report and any related services pursuant to the Terms of Use Agreement (the "Terms") on its website at www.vibrant-wellness.com. By accessing, browsing, or otherwise using the report or website or any services, you acknowledge that you have read, understood, and agree to be bound by these terms. If you do not agree to accept these terms, you shall not access, browse, or use the report or website. The statements in this report have not been evaluated by the Food and Drug Administration and are only meant to be lifestyle choices for potential risk mitigation. Please consult your physician for medication, treatment, diet, exercise or lifestyle management as appropriate. This product is not intended to diagnose, treat, or cure any disease or condition.

Please Note - It is important that you discuss any modifications to your diet, exercise and nutritional supplementation with your physician before making any changes.

LAST NAME	FIRST NAME	GENDER	DATE OF BIRTH	ACCESSION ID	DATE OF SERVICE
PATIENT	TEST2	MALE	2000-10-27	2304100001	03-10-2023 10:00

FUNGAL ANTIBODIES SUMMARY

SAMPLE

LAST NAME	FIRST NAME	GENDER	DATE OF BIRTH	ACCESSION ID	DATE OF SERVICE
PATIENT	TEST2	MALE	2000-10-27	2304100001	03-10-2023 10:00

FUNGAL ANTIBODIES COMPLETE

Candida

Test name	In Control	Moderate	High	In Control Range	Moderate Range	High Range	Previous ()
Candida albicans (IgG + IgA)							
Candida albicans IgM							
Candida tropicalis (IgG + IgA)	2.6			≤10.0	10.1~19.9	≥20.0	
Candida tropicalis IgM	5.3			≤10.0	10.1~19.9	≥20.0	
Candida parapsilosis (IgG + IgA)	2.9			≤10.0	10.1~19.9	≥20.0	
Candida parapsilosis IgM	1.1			≤10.0	10.1~19.9	≥20.0	
Candida glabrata (IgG + IgA)	7.0			≤10.0	10.1~19.9	≥20.0	
Candida glabrata IgM	6.2			≤10.0	10.1~19.9	≥20.0	
Candida krusei (IgG + IgA)	1.1			≤10.0	10.1~19.9	≥20.0	
Candida krusei IgM	1.2			≤10.0	10.1~19.9	≥20.0	
Candida lusitanae (IgG + IgA)	9.8			≤10.0	10.1~19.9	≥20.0	
Candida lusitanae IgM	3.1			≤10.0	10.1~19.9	≥20.0	
Candida dubliniensis (IgG + IgA)	8.9			≤10.0	10.1~19.9	≥20.0	
Candida dubliniensis IgM	3.0			≤10.0	10.1~19.9	≥20.0	
Candida guilliermondii (IgG + IgA)	0.1			≤10.0	10.1~19.9	≥20.0	
Candida guilliermondii IgM	8.5			≤10.0	10.1~19.9	≥20.0	

Saccharomyces

Test name	In Control	Moderate	High	In Control Range	Moderate Range	High Range	Previous ()
Saccharomyces cerevisiae (IgG + IgA)	8.9			≤10.0	10.1~19.9	≥20.0	
Saccharomyces cerevisiae IgM	8.0			≤10.0	10.1~19.9	≥20.0	

Cladosporium

Test name	In Control	Moderate	High	In Control Range	Moderate Range	High Range	Previous ()
Cladosporium (IgG + IgA)	7.6			≤10.0	10.1~19.9	≥20.0	
Cladosporium IgM	9.5			≤10.0	10.1~19.9	≥20.0	

LAST NAME	FIRST NAME	GENDER	DATE OF BIRTH	ACCESSION ID	DATE OF SERVICE
PATIENT	TEST2	MALE	2000-10-27	2304100001	03-10-2023 10:00

Trichosporon

Test name	In Control	Moderate	High	In Control Range	Moderate Range	High Range	Previous ()
Trichosporon ovoides (IgG + IgA)	8.3			≤10.0	10.1~19.9	≥20.0	
Trichosporon ovoides IgM	4.0			≤10.0	10.1~19.9	≥20.0	

SAMPLE

Risk and Limitations

This test has been developed and its performance characteristics determined by Vibrant America LLC., a CLIA certified lab. These assays have not been cleared or approved by the U.S. Food and Drug Administration.

Vibrant Fungal Antibodies panel does not demonstrate absolute positive and negative predictive values for any condition. Its clinical utility has not been fully established. Clinical history and current symptoms of the individual must be considered by the healthcare provider prior to any interventions. Test results should be used as one component of a physician's clinical assessment.

Fungal Antibodies Panel testing is performed at Vibrant America, a CLIA certified laboratory and utilizes ISO-13485 developed technology. Vibrant America has effective procedures in place to protect against technical and operational problems. However, such problems may still occur. Examples include failure to obtain the result for a specific fungal antibody due to circumstances beyond Vibrant's control. Vibrant may re-test a sample in order to obtain these results but upon re-testing the results may still not be obtained. As with all medical laboratory testing, there is a small chance that the laboratory could report incorrect results. A tested individual may wish to pursue further testing to verify any results.

The information in this report is intended for educational purposes only. While every attempt has been made to provide current and accurate information, neither the author nor the publisher can be held accountable for any errors or omissions.

Vibrant Wellness makes no claims as to the diagnostic or therapeutic use of its tests or other informational materials. Vibrant Wellness reports and other information do not constitute the giving of medical advice and are not a substitute for a professional healthcare practitioner. Please consult your provider for questions regarding test results, or before beginning any course of medication, supplementation or dietary/lifestyle changes. Users should not disregard, or delay in obtaining, medical advice for any medical condition they may have, and should seek the assistance of their health care professionals for any such conditions.